# A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

> **NCT04116710** · PHASE1 · COMPLETED · sponsor: **Heat Biologics** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** HS-110 (viagenpumatucel-L)
- **BIOLOGICAL:** HS-130

## Key facts

- **NCT ID:** NCT04116710
- **Lead sponsor:** Heat Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-18
- **Primary completion:** 2021-08-12
- **Final completion:** 2022-04-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116710, "A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04116710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*